DapaTAVI InvestigatorsRaposeiras-Roubin, S.Amat-Santos, I.J.Rossello, X.González Ferreiro, R.González Bermúdez, I.Lopez Otero, D.Nombela-Franco, L.Gheorghe, L.Diez, J.L.Baladrón Zorita, C.Baz, J.A.Muñoz García, A.J.Vilalta, V.Ojeda-Pineda, S.de la TorreHernández, J.M.Cordoba Soriano, J.G.Regueiro, A.Bordes Siscar, P.Salgado Fernández, J.Garcia Del BlancoB, .Martín-Reyes, R.Romaguera, R.Moris, C.García Blas, S.Franco-Peláez, J.A.Cruz-González, I.Arzamendi, D.Romero Rodríguez, N.Díez-Del Hoyo, F.Camacho Freire, S.Bosa Ojeda, F.Astorga Burgo, J.C.MolinaNavarro, E.Caballero Borrego, J.Ruiz Quevedo, V.Sánchez-Recalde, Á.Peral Disdier, V.Alegría-Barrero, EduardoTorres-Llergo, J.Feltes, G.Fernández Díaz, J.A.Cuellas, C.Jiménez Britez, G.Sánchez-Rubio Lezcano, J.Barreiro-Pardal, C.Núñez-Gil, I.Abu-Assi, E.Iñiguez-Romo, A.Fuster, V.Ibáñez, B.Ruiz García, Juan2026-02-232026-02-232025-04-10DapaTAVI Investigators 2025, 'Dapagliflozin in Patients Undergoing Transcatheter Aortic-Valve Implantation', New England Journal of Medicine, vol. 392, no. 14, pp. 1396-1405. https://doi.org/10.1056/NEJMoa25003660028-4793unpaywall: 10.1056/nejmoa2500366https://hdl.handle.net/10641/7921Publisher Copyright: © 2025 Massachusetts Medical Society.Background Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the risk of heart-failure admission among high-risk patients. However, most patients with valvular heart disease, including those undergoing transcatheter aortic-valve implantation (TAVI), have been excluded from randomized trials. Methods We conducted this randomized, controlled trial in Spain to evaluate the efficacy of dapagliflozin (at a dose of 10 mg once daily) as compared with standard care alone in patients with aortic stenosis who were undergoing TAVI. All the patients had a history of heart failure plus at least one of the following: renal insufficiency, diabetes, or left ventricular systolic dysfunction. The primary outcome was a composite of death from any cause or worsening of heart failure, defined as hospitalization or an urgent visit, at 1 year of follow-up. Results A total of 620 patients were randomly assigned to receive dapagliflozin and 637 to receive standard care alone after TAVI; after exclusions, a total of 1222 patients were included in the primary analysis. A primary-outcome event occurred in 91 patients (15.0%) in the dapagliflozin group and in 124 patients (20.1%) in the standard-care group (hazard ratio, 0.72; 95% confidence interval [CI], 0.55 to 0.95; P=0.02). Death from any cause occurred in 47 patients (7.8%) in the dapagliflozin group and in 55 (8.9%) in the standard-care group (hazard ratio, 0.87; 95% CI, 0.59 to 1.28). Worsening of heart failure occurred in 9.4% and 14.4% of the patients, respectively (subhazard ratio, 0.63; 95% CI, 0.45 to 0.88). Genital infection and hypotension were significantly more common in the dapagliflozin group. Conclusions Among older adults with aortic stenosis undergoing TAVI who were at high risk for heart-failure events, dapagliflozin resulted in a significantly lower incidence of death from any cause or worsening of heart failure than standard care alone.101191017enghttp://creativecommons.org/licenses/by-nc-nd/4.0/General MedicineSDG 3 - Good Health and Well-beingClinical Trial, Phase IVComparative StudyJournal ArticleMulticenter StudyPragmatic Clinical TrialRandomized Controlled Trialjournal articleinfo:eu-repo/semantics/closedAccess10.1056/NEJMoa2500366https://www.scopus.com/pages/publications/105003508965https://www.scopus.com/pages/publications/105003508965#tab=citedBy